MSCM
NBIX icon

McElhenny Sheffield Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

McElhenny Sheffield Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13
Closed -$1.55K – 419
2022
Q4 		$1.55K Buy
+13
New +$1.52K ﹤0.01% 521

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

McElhenny Sheffield Capital Management's NBIX Position: Q1 2023 in Review

McElhenny Sheffield Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 13 shares — an estimated $1.55K sold.

McElhenny Sheffield Capital Management first reported a position in NBIX in Q4 2022 and held it in 1 quarter. The position peaked at $1.55K in Q4 2022. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

  • McElhenny Sheffield Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
  • McElhenny Sheffield Capital Management sold 13 Neurocrine Biosciences shares in Q1 2023, an estimated $1.55K.
  • McElhenny Sheffield Capital Management first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 1 quarter.
  • McElhenny Sheffield Capital Management's Neurocrine Biosciences position peaked at $1.55K in Q4 2022.
  • 486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on McElhenny Sheffield Capital Management's 13F filing for Q1 2023, filed 13 Apr 2023.